> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Turalio Video Testimonial False or Misleading: OPDP
- URL: https://www.fdaweb.com/turalio-video-testimonial-false-or-misleading-opdp/
- Published: 2025-12-03T12:00:00.000Z
- Updated: 2026-09-14T15:28:12.000Z
- Author: David McFarland
- Tags: Drugs, FDA Policy/General, #legacy-id-D5160320

The CDER Office of Prescription Drug Promotion says a direct-to-consumer video for Daiichi Sankyo’s Turalio (pexidartinib) capsules, for oral use, is false or misleading and thus misbrands the drug. An 11/24 [Notice of Violation](https://www.fda.gov/media/189913/download?attachment&ref=fdaweb.com) describes the testimonial of a female patient with tenosynovial giant cell tumor (TGCT) in great detail.

“The totality of these claims and contrasting before and after presentations misleadingly suggests that treatment with Turalio will allow all patients to live as they did before their TGCT diagnosis,” the letter says, “when this has not been demonstrated. Specifically, these claims and presentations suggest that all patients with TGCT treated with Turalio will experience a complete resolution of disease and will be able to return to daily activities, for example, gardening (as in the video), without limitations from TGCT stopping them. While the patient testimonial in the video may be an accurate reflection of this patient’s own personal experience with Turalio, the testimonial does not adequately support the suggestion that other patients starting Turalio will experience a similar response.”

OPDP also says the totality of the video claims and presentations misleadingly suggests that treatment with Turalio will positively affect a patient’s health-related quality of life by improving their emotional functioning.

Daiichi Sankyo was told to respond with a list of all its promotional communications that contain representations like those described in the letter and its plan for discontinuing all such communications or for ceasing distribution of Turalio.